Enfusion Results Presentation Deck

*:enfusion ENFUSION. INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (dollars in thousands) (Unaudited) Cash flows from operating activities: Net (loss) income Adjustments to reconcile net (loss) income to net cash provided by operating activities: Non-cash operating lease expense Depreciation and amortization Provision for bad debts Amortization of debt-related costs Stock-based compensation expense Loss on extinguishment of debt Net foreign currency losses Change in operating assets and liabilities: Accounts receivable Prepaid expenses and other current assets Accounts payable Accrued expenses and other liabilities Net cash provided by (used in) operating activities Cash flows from investing activities: Purchases of property and equipment Net cash used in investing activities Cash flows from financing activities: Repayment of term loan Payment of Member distributions Issuance of Class A common stock in the IPO, net of issuance costs Purchases of common units from Pre-IPO common unit holders Payment of withholding taxes on stock-based compensation Net cash (used in) provided by financing activities Effect of exchange rate changes on cash Net (decrease) increase in cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period $ $ 2022 (13,263) 257 6,344 1,399 26 24,993 (9,031) (1,767) (843) 6,041 14,156 (7,931) (7,931) (7,959) (7,959) (86) (1,820) 64,365 62,545 $ $ 2021 PROPRIETARY AND CONFIDENTIAL (282,242) 3,975 1,450 222 289,803 1,215 (7,493) (6,477) 2,044 (2,815) (318) (8,014) (8,014) (100,000) (3,283) 260,545 (87,846) (10,567) 58,849 (90) 50,427 13,938 64,365 Ⓒ2023 ENFUSION. ALL RIGHTS RESERVED. 17

View entire presentation